 |
南京科佰生物科技有限公司
主營(yíng)產(chǎn)品： atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫(kù)購(gòu)買 |
會(huì)員.png)
11
聯(lián)系電話
|
南京科佰生物科技有限公司
主營(yíng)產(chǎn)品： atcc代理,ATCC細(xì)胞系,ATCC細(xì)胞株,ATCC細(xì)胞庫(kù)購(gòu)買 |
聯(lián)系電話
| 參考價(jià) | 面議 |
更新時(shí)間：2023-09-04 10:48:07瀏覽次數(shù)：596
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | T-25 Flask |
|---|---|---|---|
| 貨號(hào) | CBP74193 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
| CBP74193 | |
| I. Background | |
| HHLA2 (a B7 family member) has both immune inhibitory and activating abilities and is expressed in many human cancers. These differing functions rely on the receptor to which it binds, yet many of these receptors are uncharacterized. Here, Wei et al. found that KIR3DL3 bound to HHLA2 and was expressed on effector memory CD8+ T cells and CD56dim NK cells. Interactions of KIR3DL3 with tumoral HHLA2 inhibited the function and killing capacity of both CD8+ T cells and NK cells. KIR3DL3+ immune cells infiltrated various types of HHLA2+ tumors from patients with cancer, and blockade of KIR3DL3 inhibited the growth of tumors in various mouse models. Thus, KIR3DL3-HHLA2 inhibits immune-mediated clearance of tumor cells and presents a possible immunotherapeutic target for cancer. | |
| II. Introduction | |
| Expressed gene: | KIR3DL3 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Recombinant KIR3DL3 Effector Reporter Cell stably expressing KIR3DL3. | |
Figure 2. Dose Response of HHLA2 Blocking Abs in KIR3DL3 Effector Reporter Cells (C1)With HHLA2(B7H7) aAPC Cells. | |
